Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies

BACKGROUND. After erythropoiesis‐stimulating agent (ESA) failure, lenalidomide and hypomethylating agents are the only remaining treatment options for most patients with lower‐risk myelodysplastic syndromes (LR‐MDS). Optimal choice of these agents as front‐line therapy in non‐del(5q) LR‐MDS is uncle...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Komrokji, Rami, Swern, Arlene S., Grinblatt, David, Lyons, Roger M., Tobiasson, Magnus, Silverman, Lewis R., Sayar, Hamid, Vij, Ravi, Fliss, Albert, Tu, Nora, Sugrue, Mary M.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Academia‐Pharma Intersect: Hematologic Malignancies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813747/
https://ncbi.nlm.nih.gov/pubmed/29118268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0215
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados